Subscribe to RSS
Download PDF
DOI: 10.1055/s-0045-1811960
Erratum
In the article “Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms”, published in Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962, under DOI number 10.1055/s-0045-1802962,
Where it reads:
GENERAL RECOMMENDATIONS FOR THE PHARMACOLOGICAL TREATMENT OF PDD
Donepezil and rivastigmine are recommended to treat patients with PD-MCI or prodromal DLB.
Should be:
GENERAL RECOMMENDATIONS FOR THE PHARMACOLOGICAL TREATMENT OF PDD
Donepezil and rivastigmine are not recommended for the treatment of patients with PD-MCI or prodromal DLB.
Publication History
Article published online:
31 October 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
. Erratum. Arq Neuropsiquiatr 2025; 83: s00451811960.
DOI: 10.1055/s-0045-1811960